

Summary of Studies Supporting USDA Product Licensure

| Establishment Name | Hygieia Biological Laboratories | | | |
|---|---|--|--|--|
| USDA Vet Biologics Establishment Number | 407 | | | |
| Product Code | 17E1.20 | | | |
| True Name | Hemorrhagic Enteritis Vaccine, Live Virus | | | |
| Tradename(s) / Distributor or Subsidiary (if different from manufacturer) | | | | |
| Date of Compilation Summary | December 18, 2017 | | | |

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

407 17E1.20 Page 1 of 4

| Study Type | Efficacy | | | | | | |
|-------------------------------|---|--|--|--|--|--|--|
| Pertaining to | Hemorrhagic Enteritis Vaccine, Live Virus | | | | | | |
| Study Purpose | Demonstrate efficacy against virulent hemorrhagic enteritis virus | | | | | | |
| Product Administration | One dose, administered through drinking water | | | | | | |
| Study Animals | Five week old turkeys divided into 3 groups | | | | | | |
| | Group 1: vaccinated with product and challenged | | | | | | |
| | Group 2: sham vaccinated and challenged (positive control) | | | | | | |
| | Group 3: sham vaccinated, non-challenged (negative control) | | | | | | |
| Challenge Description | Domermuth strain of hemorrhagic enteritis virus administered at | | | | | | |
| | 3 weeks post vaccination | | | | | | |
| Interval observed after | Observed daily for 4 days and then evaluated for internal | | | | | | |
| challenge | changes (lesions) specific to hemorrhagic enteritis virus | | | | | | |
| | infection. | | | | | | |
| Results | Vaccinates and controls were evaluated in terms of hemorrhagic | | | | | | |
| | enteritis clinical signs and/or grossly observable lesions. | | | | | | |
| | | | | | | | |
| | No birds showed clinical signs after challenge. | | | | | | |
| | | | | | | | |
| | Birds with observable lesions: | | | | | | |
| | Group 1: 2/32 | | | | | | |
| | Group 2: 21/22 | | | | | | |
| | Group 3: 0/22 | | | | | | |
| | | | | | | | |
| | Raw data on attached page | | | | | | |
| | | | | | | | |
| LICDA Approval Data | | | | | | | |
| USDA Approval Date | | | | | | | |

407 17E1.20 Page 2 of 4

Raw data shown below for birds classified as positive. All other birds normal

| Group/Bird | Enlarged and/or marbled | Hyperemic or hemorrhagic intestine | | | |
|-------------|-------------------------|------------------------------------|--|--|--|
| | spleen | | | | |
| Group 1/340 | X | | | | |
| Group 1/357 | X | | | | |
| Group 2/303 | X | | | | |
| Group 2/305 | X | | | | |
| Group 2/310 | X | X | | | |
| Group 2/316 | X | | | | |
| Group 2/321 | X | X | | | |
| Group 2/322 | X | X | | | |
| Group 2/325 | X | X | | | |
| Group 2/327 | X | | | | |
| Group 2/331 | X | X | | | |
| Group 2/332 | X | | | | |
| Group 2/334 | X | | | | |
| Group 2/337 | X | X | | | |
| Group 2/338 | X | | | | |
| Group 2/353 | X | | | | |
| Group 2/354 | X | X | | | |
| Group 2/358 | X | X | | | |
| Group 2/361 | X | | | | |
| Group 2/362 | X | X | | | |
| Group 2/367 | X | | | | |
| Group 2/372 | X | X | | | |
| Group 2/376 | X | X | | | |

407 17E1.20 Page 3 of 4

| Study Type | Safety | | | | | | | | | |
|----------------------|--|----------------|----------|------------------|----------|-------------|-------------|--|--|--|
| Pertaining to | ALL | ALL | | | | | | | | |
| Study Purpose | Field safety | | | | | | | | | |
| Product | Single dose by drinking water route. | | | | | | | | | |
| Administration | | | | | | | | | | |
| Study Animals | Commercial turkeys at 28 to 36 days of age, 4 independent study sites. | | | | | | | | | |
| Challenge | Not ap | Not applicable | | | | | | | | |
| Description | •• | | | | | | | | | |
| Interval | Turkeys were observed for mortality and adverse reactions up to 3 weeks post | | | | | | | | | |
| observed after | vaccination. | | | | | | | | | |
| challenge | | | | | | | | | | |
| Results | | | | | | | | | | |
| | Site Number of | | | 21 Day Mortality | | % Mortality | % Mortality | | | |
| | | Turkeys | | | | | | | | |
| | | Vaccinates | Controls | Vaccinates | Controls | Vaccinates | Controls | | | |
| | 1 | 25,200 | 20,800 | 727 | 907 | 2.9 | 4.4 | | | |
| | 2 | 25,658 | 24,600 | 657 | 716 | 2.6 | 2.9 | | | |
| | 3 | 38,759 | 27,082 | 845 | 332 | 2.2 | 1.2 | | | |
| | 4 | 20,573 | 20,638 | 86 | 119 | 0.4 | 0.6 | | | |
| | No adverse reactions attributable to the vaccine were recorded. | | | | | | | | | |
| USDA | October 12, 2017 | | | | | | | | | |
| Approval Date | | | | | | | | | | |

407 17E1.20 Page 4 of 4